Skip to content

Focal therapy for prostate cancer

Treating only the tumor area, who it was studied in, what the guidelines say and what happens if it fails.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 18, 2026
Book a consultation
Drawing of the prostate in cross-section, seen from above, with the rectum below, a small tumor on one side and, around it, a treated area with a dashed outline, away from the urethra and the erection nerves
On this page

Quick answer

Focal therapy treats only the part of the prostate where the tumor is, with a margin around it, to spare the erection nerves, the sphincter and the urethra.1 Studies evaluated it mainly in intermediate-risk cancer, with one lesion visible on MRI and confirmed by biopsy.3 The 2026 European guideline recommends offering it, for intermediate risk, only within clinical trials or registries, and does not recommend focal therapy for high-risk disease.1 The American guideline considers it still investigational.2

What focal therapy is

Prostatectomy and radiotherapy treat the whole prostate. In focal therapy, only the tumor area is treated, with a margin of healthy tissue around it. The rest of the gland is left as it was.1

The goal is to reduce urinary and sexual side effects, because the nerves, the sphincter and the urethra stay away from the treated area.1 The trade-off is that the untreated tissue remains and needs to be followed.

Reviews from 2017 and 2022 counted up to eight energy sources under study, most still in early-phase studies. In the 2022 review, HIFU and photodynamic therapy had progressed furthest through the research stages.4,5 Each has its own page:

Who the studies included

Selection is the most important part. A consensus of 47 focal therapy experts agreed on these points:3

  • MRI: the standard test for selecting patients.
  • Confirmed lesion: the suspicious area on MRI must be confirmed by biopsy before treatment.
  • Systematic biopsy: still needed to check the areas MRI did not show.
  • Tumor grade: the ideal case is Gleason 3 + 4 (ISUP 2), localized and of favorable size. Some 4 + 3 (ISUP 3) cases were also accepted.
  • Size: lesions up to 1.5 mL on MRI or up to 20% of the prostate, or up to 3 mL or 25% when confined to one side.

The European guideline notes that published results come from centers with dedicated programs using MRI with targeted and systematic biopsies or mapping biopsies.1 The pages on MRI and PI-RADS and on Gleason and ISUP explain these terms.

What the guidelines say

The two main guidelines treat focal therapy with caution.

SituationEuropean guideline (2026)American guideline (2026)
Low riskFocal or whole-gland treatment is likely to be overtreatment; not to be used outside a trialInform patients that focal therapy remains investigational; active surveillance should still be offered
Intermediate riskOnly within clinical trials or registries (strong recommendation)Inform patients that it remains investigational; may be used in well-informed patients who decline standard treatments, ideally in a study
High riskDo not offer (strong recommendation)Do not recommend outside a clinical trial
Locally advancedDo not offer (strong recommendation)Do not recommend outside a clinical trial

Sources: European guideline1 and American guideline.2 The European guideline asks for these registries to follow European Medicines Agency guidance, with set follow-up times and complete data collection.1

Cancer control

Most studies have a single group, no comparison and only a few years of follow-up.4,5 The figures most often discussed with patients come from:

  • Review of 72 studies (5,827 patients): high pad-free rates and 85% to 90% without clinically significant cancer in the short term. The European guideline notes that 45% of these patients had ISUP 1 and that the quality of evidence is low.1,5
  • Comparison with prostatectomy: in an English study, 246 focal therapy patients were matched with 246 surgical patients, with PSA below 20 ng/mL and Gleason up to 4 + 3. Before matching, 420 focal therapy patients had HIFU and 81 had cryotherapy. At 8 years, 83% and 79% were free of further treatment, with no statistical difference.6 According to the European guideline, 17.1% of the focal therapy group needed retreatment.1
  • Comparison with active surveillance: in a group in which 76% of tumors were ISUP 1, focal cryotherapy showed no advantage in metastasis or survival.1

The European guideline calls for studies with standardized 15-year results before an unrestricted recommendation.1

Cancer inside and outside the treated area

Because part of the prostate is left untreated, cancer can appear in two places:

  • Inside the treated area: when the tumor was not fully destroyed. The American guideline cites rates of 10% to 40% for any cancer in the treated area and, generally, under 20% for cancer with Gleason pattern 4.2
  • Outside the treated area: a tumor that was already there and did not show on tests, or a new one. That is why a systematic biopsy is recommended before treatment.1

In a review cited by the European guideline, after one year 8.8% of patients had ISUP 2 or higher cancer in the treated area and 13% anywhere in the prostate.1

Continence and erections

This is where focal therapy stands out most in the studies.

  • In the review of 37 studies and 3,230 patients, pad-free, leak-free continence ranged from 83.3% to 100%, and erections were preserved in 81.5% to 100%. Serious adverse events ranged from 0% to 10.6%.4
  • In a review cited by the European guideline, sexual function scores fell 9% with focal therapy and 43% with whole-gland treatment.1

The comparison with surgery and radiotherapy is on the surgery or radiotherapy page, and the effects of prostatectomy are on the pages about continence and erections and ejaculation.

Follow-up: MRI and biopsy

After focal therapy, PSA alone is not enough. Part of the prostate keeps producing PSA, and it is not a reliable marker of failure.7 A consensus of 65 experts proposed:7

TestWhen
PSAEvery 3 months in the first year and every 6 months afterwards
MRIAt 6 and 18 months
BiopsyBetween 6 and 12 months: targeted to the treated area plus systematic
Urinary and sexual functionFirst assessment at 3 to 6 months, until stable

The American guideline also advises follow-up with PSA, MRI and biopsy tailored to each patient's health and cancer.2 The European guideline notes that the role of MRI and PSA in this follow-up is still being studied.1

Focal therapy, surveillance, surgery and radiotherapy

Each option has a different place in the guidelines:

OptionWhat it treatsPlace in the guidelines
Active surveillanceNothing at first; follow-up with PSA, MRI and biopsyIndicated for low risk and selected favorable intermediate-risk cases
Radical prostatectomyThe whole prostate, removedStandard treatment for intermediate and high risk
RadiotherapyThe whole prostate, irradiatedStandard treatment for intermediate and high risk, with hormone therapy when indicated
Focal therapyOnly the tumor areaInvestigational; for intermediate risk, within studies or registries

Sources: European guideline1 and American guideline.2 For favorable intermediate risk, the American guideline recommends discussing active surveillance, radiotherapy and prostatectomy (strong recommendation).2

The pages on active surveillance, robotic radical prostatectomy and radiotherapy explain each path.

When focal therapy fails

When cancer comes back, the first step is to confirm it with a biopsy. The American guideline asks for a biopsy before any local salvage treatment.9

  • Whole-gland treatment: for men being treated again after focal therapy, the American guideline recommends offering prostatectomy or radiotherapy to the whole prostate, because prostate cancer is often multifocal (expert opinion).9
  • Salvage prostatectomy: compared with surgery as the first treatment, it has more positive margins (27%), slightly more urine leakage and more early complications, most managed without further surgery.1 In a series of 82 patients who had robotic surgery after focal therapy, there were no major complications, and 83% were continent at one year. Cancer came back more often when the failure had been inside the treated area.8
  • Salvage radiotherapy: in a pooled analysis cited by the European guideline, radiotherapy after focal therapy had few side effects and PSA recurrence in about 20%.1
  • Repeat focal therapy: some patients in the studies had a second session.1,6

Positive surgical margins and PSA after prostatectomy have their own pages.

Second opinion

Many men come with a recommendation for focal therapy and want to understand whether it fits their case, or have already been treated and their PSA or MRI has changed. A second opinion can be done entirely online, in English, with your test results sent in advance. We go through the MRI, the biopsy and what the guidelines say for your risk group.

Send your case

If you are considering focal therapy, or have had it and have questions, and would like my opinion on your case before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.

Frequently asked questions

What is focal therapy for prostate cancer?

It treats only the part of the prostate where the tumor is, with a margin around it, instead of the whole gland. The aim is to spare the erection nerves, the sphincter and the urethra, to reduce urinary and sexual side effects.1 The tissue can be destroyed with cold, heat, electrical pulses, light or laser.4,5

Who can have focal therapy?

Studies mainly included men with intermediate-risk cancer (ISUP 2 and some ISUP 3), with one lesion visible on MRI and confirmed by biopsy, plus a systematic biopsy to check the rest of the prostate.1,3 The European guideline says that, for intermediate risk, it should only be done within clinical trials or registries. For high-risk and locally advanced cancer, the guideline recommends against it.1

Is focal therapy as effective as surgery?

No randomized trial has answered this yet. In an English study with 246 patients in each group, matched for cancer features, 83% of focal therapy patients and 79% of surgical patients were free of further treatment at 8 years.6 The American guideline considers focal therapy still investigational, without high-quality data comparing it with surgery, radiotherapy and active surveillance.2

Can cancer come back after focal therapy?

Yes, inside the treated area or in another part of the prostate that was left untreated. In a review cited by the European guideline, after one year 8.8% had ISUP 2 or higher cancer in the treated area and 13% anywhere in the prostate.1 That is why follow-up includes PSA, MRI and biopsy.7

Does focal therapy affect erections and continence?

Less than whole-gland treatments, according to the reviews. In a review of 37 studies, pad-free continence ranged from 83.3% to 100%, and erections were preserved in 81.5% to 100%.4 In a review cited by the European guideline, sexual function scores fell 9% with focal therapy and 43% with whole-gland treatment.1

What is follow-up like after focal therapy?

An international consensus proposes PSA every 3 months in the first year and every 6 months afterwards, MRI at 6 and 18 months, and a biopsy of the treated area plus a systematic biopsy between 6 and 12 months.7 The European guideline notes that there is still no well-defined follow-up pathway.1

If focal therapy fails, can I still have surgery or radiotherapy?

Yes. The American guideline recommends offering whole-gland treatment with prostatectomy or radiotherapy.9 Prostatectomy after focal therapy has more positive margins (27%) and slightly more urine leakage than surgery as the first treatment.1 In a series of 82 patients, there were no major complications, and 83% were continent at one year.8

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
  2. Eastham JA, Barocas DA, Chu CE, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026). J Urol. 2026;216(1):2-11. PubMed
  3. Tay KJ, Scheltema MJ, Ahmed HU, et al. Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project. Prostate Cancer Prostatic Dis. 2017;20(3):294-299. PubMed
  4. Valerio M, Cerantola Y, Eggener SE, et al. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol. 2017;71(1):17-34. PubMed
  5. Hopstaken JS, Bomers JGR, Sedelaar MJP, et al. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol. 2022;81(1):5-33. PubMed
  6. Shah TT, Reddy D, Peters M, et al. Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. Prostate Cancer Prostatic Dis. 2021;24(2):567-574. PubMed
  7. Lebastchi AH, George AK, Polascik TJ, et al. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. Eur Urol. 2020;78(3):371-378. PubMed
  8. Marconi L, Stonier T, Tourinho-Barbosa R, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol. 2019;76(1):27-30. PubMed
  9. Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024;211(4):526-532. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation5.0186 Google reviews

Related guides